FI942622A - Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi - Google Patents

Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi Download PDF

Info

Publication number
FI942622A
FI942622A FI942622A FI942622A FI942622A FI 942622 A FI942622 A FI 942622A FI 942622 A FI942622 A FI 942622A FI 942622 A FI942622 A FI 942622A FI 942622 A FI942622 A FI 942622A
Authority
FI
Finland
Prior art keywords
growth factor
fibrosis
extracellular matrix
transforming growth
factor beta
Prior art date
Application number
FI942622A
Other languages
English (en)
Swedish (sv)
Other versions
FI942622A0 (fi
Inventor
Erkki I Ruoslahti
Wayne A Border
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Publication of FI942622A0 publication Critical patent/FI942622A0/fi
Publication of FI942622A publication Critical patent/FI942622A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI942622A 1991-12-04 1994-06-03 Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi FI942622A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80328591A 1991-12-04 1991-12-04
PCT/US1992/010550 WO1993010808A1 (en) 1991-12-04 1992-12-04 INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX

Publications (2)

Publication Number Publication Date
FI942622A0 FI942622A0 (fi) 1994-06-03
FI942622A true FI942622A (fi) 1994-07-27

Family

ID=25186123

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942622A FI942622A (fi) 1991-12-04 1994-06-03 Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi

Country Status (10)

Country Link
EP (1) EP0616536B1 (fi)
JP (2) JP3854307B2 (fi)
AT (1) ATE177644T1 (fi)
AU (2) AU670770B2 (fi)
CA (1) CA2124591A1 (fi)
DE (1) DE69228700T2 (fi)
DK (1) DK0616536T3 (fi)
FI (1) FI942622A (fi)
NO (1) NO942072L (fi)
WO (1) WO1993010808A1 (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
DE69434617D1 (de) * 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
WO1995026203A1 (en) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Wound healing
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
AU1826799A (en) * 1998-01-09 1999-07-26 University Of Utah, The Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by tgfbeta using renin inhibitors
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
DE60230877D1 (de) 2001-08-15 2009-03-05 Univ Brown Res Found Behandlung von muskeldystrophien und verwandter erkrankungen
CA2473829A1 (en) * 2002-01-22 2003-07-31 Genzyme Corporation Use of tgf-.beta. antagonists to treat or to prevent chronic transplant rejection
WO2004075917A1 (ja) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. 器官または組織の線維化抑制剤
JP5602365B2 (ja) 2005-10-25 2014-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ マルファン症候群及び関連疾患を治療するための方法及び組成物。
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP1983345A1 (en) * 2007-04-17 2008-10-22 Roche Diagnostics GmbH Means and method for assessing the risk of a cardiac intervention in patients suffering from a stable coronary heart disease based on GDF-15
HUE040107T2 (hu) 2010-03-12 2019-02-28 Genzyme Corp Kombinációs terápia mellrák kezelésére
WO2011146480A1 (en) 2010-05-17 2011-11-24 Brown University Biglycan mutants and related therapeutics and methods of use
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
CA2823194A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
PT2714735T (pt) 2011-06-03 2021-10-26 Xoma Technology Ltd Anticorpos específicos para tgf-beta
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017223268A1 (en) * 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
JP7109039B2 (ja) 2016-07-07 2022-07-29 国立大学法人千葉大学 抗線維症剤およびリン酸化Ｓｍａｄ核内移行阻害剤
KR102141125B1 (ko) * 2018-01-22 2020-08-05 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
WO2019143219A1 (ko) * 2018-01-22 2019-07-25 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
US20220160821A1 (en) * 2019-04-11 2022-05-26 Korea University Research And Business Foundation Pharmaceutical composition for preventing or treating obesity containing biglycan as active ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654938B2 (en) * 1989-09-29 1994-12-01 La Jolla Cancer Research Foundation Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors

Also Published As

Publication number Publication date
FI942622A0 (fi) 1994-06-03
JP2004043507A (ja) 2004-02-12
DE69228700D1 (de) 1999-04-22
AU7051896A (en) 1997-01-16
WO1993010808A1 (en) 1993-06-10
EP0616536A1 (en) 1994-09-28
CA2124591A1 (en) 1993-06-10
AU3242993A (en) 1993-06-28
ATE177644T1 (de) 1999-04-15
DE69228700T2 (de) 1999-09-09
NO942072L (no) 1994-08-03
DK0616536T3 (da) 1999-10-11
AU670770B2 (en) 1996-08-01
EP0616536B1 (en) 1999-03-17
JPH07504650A (ja) 1995-05-25
JP3854307B2 (ja) 2006-12-06
NO942072D0 (no) 1994-06-03

Similar Documents

Publication Publication Date Title
FI942622A (fi) Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi
ATE193541T1 (de) Insulinotropes hormon
Roberge et al. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop
Remuzzi et al. Haemolytic-uraemic syndrome: deficiency of plasma factor (s) regulating prostacyclin activity?
El-sherif et al. Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations
DE60023492D1 (de) Glucagon antagonisten/inverse agonisten
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
EP1123129A4 (en) SYSTEMS AND COMPOUNDS FOR ADMINISTRATION OF MEDICINE IN INTERSTITIAL REGIONS OF MYOCARD
NO921119L (no) Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks
RU94013439A (ru) Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения
ES2054995T3 (es) Nuevos derivados del acido benzoico y acido fenilacetico, su obtencion y empleo como medicamentos.
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
JPS6429308A (en) Treatment of hyperhydrosis, psoriasis and wrinkle
ATE410506T1 (de) Behandlung der pompeschen krankheit
DE60000288T2 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
AU2020200934A1 (en) Long-acting adrenomedullin derivative
Doi et al. Vascular endothelial growth factor suppresses C-type natriuretic peptide secretion
DK47089D0 (da) Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer
AR240926A2 (es) "procedimiento para la preparacion de 8-isopropil-6-dimetilamino metil-7-hidroxi-4-metil-cumarina".
Louis et al. A diabetogenic polypeptide from bovine adenohypophysis similar to that excreted in lipoatrophic diabetes
Sassolas et al. Nocturnal continuous infusion of growth hormone (GH)-releasing hormone results in a dose-dependent accentuation of episodic GH secretion in normal men
LV11987A (lv) Aptaukosanas noversanas vai arstesanas metode
Plack et al. Complete heart block developing during aortic valvuloplasty
Höllt et al. Increased biosynthesis of β-endorphin in the pars intermedia of rat pituitaries after long-term treatment with haloperidol
UA72871C2 (uk) Засіб для лікування та профілактики цукрового діабету та спосіб лікування

Legal Events

Date Code Title Description
FD Application lapsed